Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1998-1-16
|
pubmed:abstractText |
The role of int-2 oncogene amplification on the prognosis of breast cancer patients was investigated in 128 patients with node-negative primary breast cancers given first-line local-regional treatments until relapse and with a median follow-up of 65 months. Tumours had been previously characterised for oestrogen (ER) and progesterone receptor (PgR) status and proliferative activity (3H-thymidine labelling index). Amplification of the int-2 oncogene occurred in 18% of cases and was significantly related to the presence of hormone receptors and to menopausal status or age, but not to proliferative status. Patients with tumours exhibiting int-2 amplification had a lower probability of disease-free survival than patients with non-amplified tumours and frequently developed local-regional recurrence. Disease-free survival analysis, adjusted for the prognostic contribution provided by tumour size, steroid receptors and proliferative rate, indicated that the association between int-2 amplification and risk of relapse was maintained and remained constant even in the presence of the other co-variates. Interestingly, int-2 amplification was a further prognostic discriminant within subsets of patients with a putatively good (i.e., tumour size <20 mm, ER+ and PgR+) or poor prognosis (i.e., high labelling index). Our exploratory study suggests that within node-negative patients, int-2 amplification could be a valuable and independent prognosticator, useful to identify patients at high risk of local-regional recurrence.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/FGF3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Fibroblast Growth Factor 3,
http://linkedlifedata.com/resource/pubmed/chemical/Fibroblast Growth Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
19
|
pubmed:volume |
74
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
620-4
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:9421359-Analysis of Variance,
pubmed-meshheading:9421359-Breast Neoplasms,
pubmed-meshheading:9421359-DNA, Neoplasm,
pubmed-meshheading:9421359-Disease-Free Survival,
pubmed-meshheading:9421359-Female,
pubmed-meshheading:9421359-Fibroblast Growth Factor 3,
pubmed-meshheading:9421359-Fibroblast Growth Factors,
pubmed-meshheading:9421359-Gene Amplification,
pubmed-meshheading:9421359-Humans,
pubmed-meshheading:9421359-Lymph Nodes,
pubmed-meshheading:9421359-Middle Aged,
pubmed-meshheading:9421359-Prognosis,
pubmed-meshheading:9421359-Proportional Hazards Models,
pubmed-meshheading:9421359-Proto-Oncogene Proteins,
pubmed-meshheading:9421359-Receptors, Estrogen
|
pubmed:year |
1997
|
pubmed:articleTitle |
int-2 oncogene amplification and prognosis in node-negative breast carcinoma.
|
pubmed:affiliation |
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|